30.11.2023 15:00
TOLREMO therapeutics AG, the startup on a mission to prevent non-genetic cancer drug resistance, has dosed the first patient in its first-in-human clinical trial evaluating the safety and tolerability, pharmacokinetics, and pharmacodynamics of its lead candidate, TT125-802, in patients across a range of solid tumor indications.